SCHEMBL26686338

SCHEMBL26686338

Clc1ccnc2[nH]c(CCCN3CCOCC3)cc12

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CCNK O75909 2/20 0.47
▸ CDK12 Q9NYV4 2/20 0.47
▸ SIGMAR1 Q99720 5/20 0.42
▸ CDC7 O00311 1/20 0.41
▸ PIM1 P11309 1/20 0.41
▸ CDK9 P50750 1/20 0.41
▸ DRD2 P14416 1/20 0.41
▸ DRD4 P21917 1/20 0.41
▸ DRD3 P35462 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ IDE P14735 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ LCK P06239 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26686635 0.93 CCNK (0.48) CCNKCDK12SIGMAR1CDC7PIM1
SCHEMBL26889438 0.88 HRH3 (0.44) CDC7PIM1CDK9DRD2DRD4
SCHEMBL26686575 0.85 CCNK (0.58) CCNKCDK12CDC7PIM1CDK9
SCHEMBL26889405 0.80 DRD2 (0.46) CCNKCDK12SIGMAR1CDC7PIM1
SCHEMBL26686172 0.75 JAK2 (0.51) CCNKCDK12
SCHEMBL31240772 0.73 CSF1R (0.67) CDC7PIM1CDK9LCK
SCHEMBL26686463 0.73 CDK9 (0.42) CCNKCDK12CDC7PIM1CDK9
SCHEMBL26889338 0.73 CCNK (0.58) CCNKCDK12CDC7PIM1CDK9
SCHEMBL26889371 0.72 CCNK (0.45) CCNKCDK12CDC7PIM1CDK9
SCHEMBL26889301 0.72 CCNK (0.45) CCNKCDK12CDC7PIM1CDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304576-A1 IKK INHIBITORS CANCER RESEARCH TECH LTD (GB) 2025-10-02 — — US disclosed
EP-4522597-A1 IKK INHIBITORS Cancer Research Technology Limited (GB) 2025-03-19 — — EP disclosed
CN-119562945-A IKK inhibitors 癌症研究技术有限公司 2025-03-04 — — CN disclosed
WO-2023218201-A1 IKK INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-11-16 — — WO disclosed
WO-2023218201-A1 IKK INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-11-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304576-A1 IKK INHIBITORS NFKBIA, IKBKE, IKBKB CCNK 222/4885CDK12 171/4885SIGMAR1 3594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback